Phase IIIb, open‐label single‐arm trial of darunavir/cobicistat (DRV/COBI): Week 48 subgroup analysis of HIV‐1‐infected treatment‐nave adults

Introduction COBI, a PK enhancer with no ARV activity is a more selective cytochrome P450 (CYP)3A inhibitor than ritonavir (RTV), does not induce CYP isozymes, and thus has less potential for drug‐drug interactions. COBI boosts DRV PK as effectively as RTV in healthy volunteers. Materials and Method...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the International AIDS Society 2014-11, Vol.17 (4 Suppl 3), p.19772-n/a
Hauptverfasser:	Tashima, Karen, Crofoot, Gordon, Tomaka, Frank L, Kakuda, Thomas N, Brochot, Anne, Vanveggel, Simon, Opsomer, Magda, Garner, William, Margot, Nicolas, Custodio, Joseph M, Fordyce, Marshall W, Szwarcberg, Javier
Format:	Artikel
Sprache:	eng
Schlagworte:	Acquired immune deficiency syndrome AIDS Creatinine HIV Human immunodeficiency virus Hypersensitivity Ritonavir
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!